1. Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia— Lessons Learned from the Prospective BRIDGE Trial 
Jan Moritz Middeke, Regina Herbst, Stefani Parmentier, Gesine Bug, Mathias Hänel, Gernot Stuhler, Kerstin Schäfer-Eckart, Wolf Rösler, Stefan Klein, Wolfgang Bethge, Ulrich Bitz, Bozena Büttner, Holger Knoth, Nael Alakel, Markus Schaich, Anke Morgner, Michael Kramer, Katja Sockel, Malte von Bonin, Friedrich Stölzel, Uwe Platzbecker, Christoph Röllig, Christian Thiede, Gerhard Ehninger, Martin Bornhäuser, Johannes Schetelig 
Biology of Blood and Marrow Transplantation 
Volume 23, Issue 9, Pages (September 2017)
DOI: /j.bbmt
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Overall and relapse-free survival. (A) OS together with Greenwood 95% CI from study enrollment for all enrolled patients (n = 84). (B) RFS together with Greenwood 95% CI for all patients with a documented CR/CRi (n = 50) after allogeneic HSCT calculated from the time of allogeneic HSCT.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Changes of the HCT-CI during course of treatment. Changes of the HCT-CI between study enrollment and start of conditioning before HSCT in patients who received transplants. Median value is shown for the HCT-CI and mean values for its single items at time of study enrollment and at HSCT. The HCT-CI increased from a median of 1 (observed range of score, 0 to 6; interquartile range, 0 to 3) at the time of study enrollment to a median of 2 (observed range of score, 0 to 7; interquartile range, 1 to 4) at the time of start of the conditioning regimen.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Survival according to HCT-CI and ECOG. (A) Impact of the HCT-CI at the time of study enrollment for all enrolled patients on OS in univariate comparisons calculated from study enrollment, P = .042. (B) Impact of the ECOG (0 and 1 versus ≥2) score at the time of study enrollment for all enrolled patients on OS in univariate comparisons calculated from study enrollment, P ≤ .005.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions